643067-83-8

Basic information

• Product Name: 8-BroMo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine
• Synonyms: 8-BroMo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine;1,4-Dioxino[2,3-b]pyridine, 8-bromo-2,3-dihydro-
• CAS NO: 643067-83-8
• Molecular Formula: C7H6BrNO2
• Molecular Weight: 216.03204
• Mol File: 643067-83-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-BroMo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BroMo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine(643067-83-8)
• EPA Substance Registry System: 8-BroMo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine(643067-83-8)

Safety Data

• Hazardous Substances Data: 643067-83-8(Hazardous Substances Data)

Usage

General Description

8-Brom-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine, also known as BDPP, is a chemical compound with the molecular formula C7H8BrNO2. It is a nitrogen-containing heterocyclic compound with a six-membered ring containing both oxygen and nitrogen atoms. BDPP has been studied for its potential pharmaceutical applications, particularly as a precursor in the synthesis of various organic compounds. It is also known for its role as an intermediate in chemical reactions for the production of materials used in pharmaceutical and agricultural applications. BDPP has also been researched for its potential biological activity and its interaction with various biological systems. Further studies are needed to fully understand the potential uses and effects of 8-Brom-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine.

Upstream product

• 129421-32-5 2,3-dihydro-1,4-dioxino<2,3-b>pyridine 

Downstream Products

• 1229624-31-0 C₁₉H₂₇N₃O₆ 

Relevant articles and documents

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula (I) or pharmaceutically acceptable salt thereof wherein ring A represents group A-I, A-II or A-III. Al represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A2 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A3 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A4 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A5 represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A6 represents -C(R4c)(R4c)- or -C(R4c)=; A7 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A8 represents -C(R4a)(R4a)-, -N(R4b)-, -O- or -S-; A9 represents -C(R4c)(R4c)- or -0-; A10 represents -C(R4c)(R4c)- or -0-; A11 represents -C(R4c)(R4c)- or -0-; A12 represents -C(R4a)(R4a)-, -O- or -S-; wherein group A-I, group A-II and group A-III de not contain adjacent oxygen atoms, adjacent oxygen and sulfur atoms or adjacent oxygen and nitrogen atoms or a moiety selected from the group consisting of N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S, wherein in each case the carbon atom in the N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S moiety is saturated; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a, R4b and R4c are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.